Navigation Links
Researchers observe single protein dimers wavering between two symmetrically opposed structures
Date:6/19/2009

tremely large number of structures even with a single chain of amino acids, end up folding themselves to a well defined three-dimensional structural basin," says Deniz." While the concept of a funneled energy landscape explains folding, protein function often requires more than one stable three-dimensional shape. Theoretical work generalizing energy landscape theory combined with these experiments shed light on how symmetry can result in proteins being able to populate structures that are dramatically different, a feature very important in cellular regulation and function."

A deeper understanding of how living systems use protein shape shifting to control cellular processes would allow better design of therapeutics that can alter these shapes in order to turn proteins on and off and control disease, Deniz notes.

Head or Tail?

In the new study, the researchers examined a protein known as Rop (repressor of primer), expressed in E. coli bacteria, which binds to RNA to regulate the number of copies of plasmid genes produced within the bacteria. This small "homodimer" is made up of two identical hairpin coils of amino acids, and has often been used as a model system to study protein structure and stability.

The protein has been found in two different conformations: the "anti" wild type (natural) conformation occurs when the "head" of one hairpin is paired with the "tail" of the second, and the "syn" structure is made up of the two bound head-to-head. The anti structure is thought to be the active conformation that binds to RNA, while the syn structurefound in a mutantis inactive.

But theorist Onuchic and his coworkers had proposed that there is a delicate balance of energy for the syn and anti structures, with mutations or conditions being able to alter this balance. They predicted that certain mutations in the protein sequence would allow a single sequence to populate both structures, which they felt might explain puzzling
'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Caltech researchers explore how cells reconcile mixed messages in decisions about growth
2. UC Davis researchers visualize formation of a new synapse
3. UBC researchers develop new method to study gambling addictions
4. UCLA cancer researchers develop model that may help identify cancer stem cells
5. Researchers from around the globe coming to K-State June 21 for workshop on Fusarium fungus
6. Duke, Harvard researchers to monitor bonobo reintroduction
7. Rice University researchers ask if biofuels will lead to a drink or drive
8. Aussie and Kiwi researchers make double MS genetic discovery
9. Researchers describe implausible chemistry that produces herbicidal compound
10. Universitat Autonoma de Barcelona researchers first to clone mice in Spain
11. Protein that triggers plant cell division revealed by researchers
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lyric Presents the Sounds of the Season 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4